Hiroshi Semba

1.5k total citations
46 papers, 1.1k citations indexed

About

Hiroshi Semba is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Hiroshi Semba has authored 46 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Pulmonary and Respiratory Medicine, 29 papers in Oncology and 10 papers in Surgery. Recurrent topics in Hiroshi Semba's work include Lung Cancer Research Studies (24 papers), Lung Cancer Treatments and Mutations (24 papers) and Lung Cancer Diagnosis and Treatment (15 papers). Hiroshi Semba is often cited by papers focused on Lung Cancer Research Studies (24 papers), Lung Cancer Treatments and Mutations (24 papers) and Lung Cancer Diagnosis and Treatment (15 papers). Hiroshi Semba collaborates with scholars based in Japan, United States and Germany. Hiroshi Semba's co-authors include Takashi Seto, Kazuhiko Nakagawa, Koji Takeda, Nobuyuki Katakami, Shinji Fujii, Masahiro Fukuoka, Toshiyuki Sawa, Shunichi Negoro, Kosuke Kashiwabara and Masahiko Ando and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

Hiroshi Semba

42 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hiroshi Semba Japan	15	962	629	127	110	53	46	1.1k
Enjô Hata Japan	9	637 0.7×	395 0.6×	181 1.4×	103 0.9×	84 1.6×	31	864
Akira Haro Japan	14	448 0.5×	373 0.6×	100 0.8×	118 1.1×	76 1.4×	42	750
Yoji Fukumoto Japan	19	498 0.5×	480 0.8×	363 2.9×	68 0.6×	45 0.8×	66	953
Anne-Marie Ruppert France	14	534 0.6×	400 0.6×	113 0.9×	175 1.6×	51 1.0×	51	777
Claudia Bareggi Italy	12	211 0.2×	516 0.8×	106 0.8×	82 0.7×	85 1.6×	38	721
Kazutoshi Isobe Japan	13	704 0.7×	294 0.5×	98 0.8×	144 1.3×	29 0.5×	109	926
H. Le Caer France	13	555 0.6×	523 0.8×	133 1.0×	74 0.7×	41 0.8×	49	819
Toshiteru Tokunaga Japan	15	655 0.7×	248 0.4×	215 1.7×	60 0.5×	150 2.8×	55	853
Hirohiko Kuroda Japan	16	350 0.4×	347 0.6×	256 2.0×	29 0.3×	33 0.6×	46	681
Ángel Olazábal Spain	8	895 0.9×	445 0.7×	178 1.4×	54 0.5×	137 2.6×	11	1.1k

Countries citing papers authored by Hiroshi Semba

Since Specialization

Citations

This map shows the geographic impact of Hiroshi Semba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroshi Semba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroshi Semba more than expected).

Fields of papers citing papers by Hiroshi Semba

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroshi Semba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroshi Semba. The network helps show where Hiroshi Semba may publish in the future.

Co-authorship network of co-authors of Hiroshi Semba

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroshi Semba. A scholar is included among the top collaborators of Hiroshi Semba based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroshi Semba. Hiroshi Semba is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kashiwabara, Kosuke, Shinji Fujii, Shinsuke Tsumura, Kazuhiko Sakamoto, & Hiroshi Semba. (2021). Efficacy and safety of transbronchial microwave ablation therapy under moderate sedation in malignant central airway obstruction patients with respiratory failure: a single-institution retrospective study. Journal of Cancer Research and Clinical Oncology. 147(9). 2751–2757. 6 indexed citations

Kashiwabara, Kosuke, Shinji Fujii, Shinsuke Tsumura, Kazuhiko Sakamoto, & Hiroshi Semba. (2019). Additional bevacizumab in EGFR-mutant lung adenocarcinoma patients who had oligo-progression after the failure of EGFR-TKI: A single-institute retrospective study. Cancer Treatment and Research Communications. 22. 100163–100163. 4 indexed citations

Kashiwabara, Kosuke, Hiroshi Semba, Shinji Fujii, & Shinsuke Tsumura. (2018). Re-administration of Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer Who Recovered from Chemotherapy-induced Interstitial Lung Disease. In Vivo. 32(4). 851–857. 1 indexed citations

Kashiwabara, Kosuke, Hiroshi Semba, Shinji Fujii, & Shinsuke Tsumura. (2017). Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease. Cancer Chemotherapy and Pharmacology. 79(4). 705–710. 24 indexed citations

Sakata, Shinya, Sho Saeki, Isamu Okamoto, et al.. (2016). Phase II trial of weekly nab-paclitaxel for previously treated advanced non–small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301. Lung Cancer. 99. 41–45. 22 indexed citations

Kashiwabara, Kosuke, Hiroshi Semba, Shinji Fujii, & Shinsuke Tsumura. (2016). Tolerability and efficacy of afatinib at a low starting dosage in 10 elderly or low performance status patients with advanced refractory non-small-cell lung cancer. Respiratory Investigation. 54(6). 468–472. 5 indexed citations

Kashiwabara, Kosuke, et al.. (2015). Difference in benefit of chemotherapy between small cell lung cancer patients with interstitial pneumonia and patients with non-small cell lung cancer.. PubMed. 35(2). 1065–71. 15 indexed citations

Kawano, Yuko, Isamu Okamoto, Haruhiko Fukuda, et al.. (2014). Current status and future perspectives of cooperative study groups for lung cancer in Japan. Respiratory Investigation. 52(6). 339–347. 3 indexed citations

Asano, Fumihiro, Motoi Aoe, Yoshinobu Ohsaki, et al.. (2013). Complications associated with endobronchial ultrasound-guided transbronchial needle aspiration: a nationwide survey by the Japan Society for Respiratory Endoscopy. Respiratory Research. 14(1). 50–50. 175 indexed citations

10.

Takeda, Kazuhisa, Shunichi Negoro, Masahiro Tanaka, et al.. (2010). A Phase II Study of Cisplatin and Irinotecan As Induction Chemotherapy Followed by Concomitant Thoracic Radiotherapy with Weekly Low-dose Irinotecan in Unresectable, Stage III, Non-Small Cell Lung Cancer: JCOG 9706. Japanese Journal of Clinical Oncology. 41(1). 25–31. 7 indexed citations

11.

Takeda, Koji, Shunichi Negoro, Tomohide Tamura, et al.. (2009). Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104). Annals of Oncology. 20(5). 835–841. 57 indexed citations

12.

Seto, Takashi, Takeharu Yamanaka, Makiko Nakano, et al.. (2008). Tegafur-Uracil Plus Gemcitabine Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with Platinum. Journal of Thoracic Oncology. 3(6). 637–642. 2 indexed citations

13.

Ebi, Noriyuki, Hiroshi Semba, Koichi Takayama, et al.. (2008). A Phase II Trial of Gefitinib Monotherapy in Chemotherapy-Naïve Patients of 75 Years or Older with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 3(10). 1166–1171. 37 indexed citations

14.

Saito, Hiroshi, Shinzoh Kudoh, Kazuhiko Nakagawa, et al.. (2006). Phase II Study of 3-Week Scheduling of Irinotecan in Combination With Cisplatin in Patients With Advanced Nonsmall-Cell Lung Cancer. American Journal of Clinical Oncology. 29(5). 503–507. 3 indexed citations

15.

Seto, Takashi, Sunao Ushijima, Hidehiko Yamamoto, et al.. (2006). Intrapleural hypotonic cisplatin treatment for malignant pleural effusion in 80 patients with non-small-cell lung cancer: a multi-institutional phase II trial. British Journal of Cancer. 95(6). 717–721. 34 indexed citations

16.

Okamoto, Isamu, Akinobu Hamada, Yusuke Matsunaga, et al.. (2005). Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer. Cancer Chemotherapy and Pharmacology. 57(3). 282–288. 30 indexed citations

17.

Ichinose, Y., Takashi Seto, Hiroshi Semba, et al.. (2005). UFT plus gemcitabine combination chemotherapy in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial. British Journal of Cancer. 93(7). 770–773. 11 indexed citations

18.

Seto, Takashi, et al.. (2004). Doublet regimen of cisplatin plus docetaxel for second-line chemotherapy after prior therapy with cisplatin plus irinotecan for non-small cell lung cancer: a phase II study. International Journal of Clinical Oncology. 9(5). 378–382. 7 indexed citations

19.

Seto, Takashi, et al.. (2002). A phase I study of combination chemotherapy with gemcitabine and oral UFT for advanced non-small cell lung cancer. British Journal of Cancer. 86(11). 1701–1704. 11 indexed citations

20.

Seto, Takashi, et al.. (1997). Two Cases of Epitheloid Sarcoma with Pulmonary Metastasis Presenting as Thin-walled Cavities.. Haigan. 37(7). 1003–1008.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact